ProCE Banner Activity

Evolving Treatment Landscape With Regorafenib and TAS-102 in Metastatic Colorectal Cancer

Podcast Episodes
Listen to Nilofer S. Azad, MD, and Kanwal Raghav, MD, as they discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC.

Released: April 06, 2022

Expiration: April 05, 2023

No longer available for credit.

Share

Faculty

Nilofer S. Azad

Nilofer S. Azad, MD

Associate Professor, Oncology
Johns Hopkins
Baltimore, Maryland

Kanwal Raghav

Kanwal Raghav, MD

Associate Professor
Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

Nilofer S. Azad, MD

Associate Professor, Oncology
Johns Hopkins
Baltimore, Maryland

Nilofer S. Azad, MD, has disclosed that she has received funds for research support from Astex, Agios, Bayer, Bristol-Myers Squibb, Daiichi, Debio, Incyte, Intensity, Lilly, Merck/EMD Serono, Syndax, and Taiho and consulting fees from Merck/EMD Serono and QED.

Kanwal Raghav, MD

Associate Professor
Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Kanwal Raghav, MD, has disclosed that he has received funds for research support from Bayer, Daiichi, Medimmune, Merck, and Roche; consulting fess from Bayer and Daiichi; and fees for non-CME/CE services from Daiichi.